Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 11INDUSTRY 6NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 40Sarcoma 2Thoracic 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 264Leukemia, Lymphocytic, Chronic, B-Cell 249Leukemia, Myeloid, Acute 236Leukemia 235Lymphoma 177Lymphoma, Non-Hodgkin 168Lymphoma, Follicular 154Burkitt Lymphoma 146Lymphoma, Large B-Cell, Diffuse 142Lymphoma, B-Cell, Marginal Zone 135Lymphoma, Mantle-Cell 133Lymphoma, Large-Cell, Immunoblastic 115Hodgkin Disease 109Myelodysplastic Syndromes 107Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 96Congenital Abnormalities 90Multiple Myeloma 86Lymphoma, T-Cell, Cutaneous 81Lymphoma, Large-Cell, Anaplastic 76Hematologic Neoplasms 75Leukemia, Myelomonocytic, Chronic 74Waldenstrom Macroglobulinemia 73Immunoblastic Lymphadenopathy 70Leukemia, Myelomonocytic, Acute 69Sezary Syndrome 68Mycosis Fungoides 68Blast Crisis 68Leukemia, Monocytic, Acute 62Myeloproliferative Disorders 61Leukemia, Myelogenous, Chronic, BCR-ABL Positive 61

Interventions

Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Skin Neoplasms × Other hematologic neoplasm × Clear all
NCT00563290 2015-06-18

Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
7 enrolled 6 charts
DermatologicLymphoidOther hematologic neoplasm

Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡